Overview

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Status:
Completed

Trial end date:
2018-10-17

Target enrollment:

Participant gender:

Summary

This is a safety / feasibility trial evaluating the combination of a humanized anti-GD2 antibody (HU14.18K322A) manufactured at the Children's GMP, LLC at St. Jude with allogeneic natural killer (NK) cells and standard chemotherapy in children with relapsed or refractory neuroblastoma.

Phase:

Phase 1

Details

Lead Sponsor:

St. Jude Children's Research Hospital

Collaborator:

CURE Childhood Cancer, Inc.

Treatments:

Aldesleukin
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Sargramostim